Ivermectin has been reported to be a SARS-CoV-2 inhibitor. This activity is believed to be due to the dependence of many different RNA viruses on IMPα / β1 during infection. These reports suggested that the inhibitory activity of ivermectin nuclear transport may be effective against SARS-CoV-2, since they demonstrate that ivermectin has antiviral action against the clinical isolate of SARS-CoV-2 in vitro, with a single dose capable to control viral replication in 24-48 hours. in vitro

Severe Acute Respiratory Syndrome

Ventilation Pneumonitis

Ivermectin 5 MG/ML

Hospital Eurnekian

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19

Considering healing and/or reducing symptoms and severity of initial presentation

Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive care

potential need of reducing or augmenting doses

Outcome of adverse effects to one or more drugs used in the clinical trial

Personal data will remain secret. Only clinical descriptions (age, gender, co-morbidities, evolution, outcomes will be released

Hector E Carvallo

Principal investigator

Eurnekian Public Hospital

17 patients received continuous medication with salsalate 2g/day after run-in period

17 patients received continuous medication with Placebo 2g/day after run-in period

Non Alcoholic Fatty Liver

Osteo Arthritis

Medicate salsalate 2g/day after run-in period
Check side effect after 1 month and Control dosage (2g/day or 3g/day)
Check side effect after 2 month

Salsalate

Medicate placebo 2g/day after run-in period
Check side effect after 1 month and Control dosage (2g/day or 3g/day)
Check side effect after 2 month

Placebo

Korea University Guro Hospital

The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease

The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study

Estimation of salsalate single injection group and placebo injection group

Estimation with treatment-related adverse events as assessed by CTCAE v4.0

Ji Hoon Kim

Associate professor

Kuhnil Pharmaceutical Co., Ltd.

Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides

Melasma

Modified Jessner's solution will be applied on the right side until frosting

Modified Jessner's solution

Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes

Glycolic acid

Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting

Trichloroacetic acid

Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid

The Efficacy of Combined Peels in Treatment of Melasma Using Modified Jessner's Solution With 20%Trichloroacetic Acid Versus 70%Glycolic Acid With 20% Trichloroacetic Acid : A Split-face Study

MASI = .3A(D+H) [forhead] + .3A(D+H)[right malar] + .3A(D+H)[left malar] + .1A(D+H)[chin]; A = area, D = darkness, and H = homogeneity. Area is based on percentage of the region covered by melasma using a 1-6 scale. Darkness is determined on a 0-3 scale. Homogeneity is based on a 0-4 scale.

Photos were evaluated using the grading of worse, no improvement, mild improvement or marked improvement comparing week 12 to baseline.

Ereny Ramsis

Principal Investigator

Assiut University

Cutaneous Leishmaniasis

daily nitric oxide patch application during 20 days

controlled nitric oxide releasing patch

meglumine antimoniate

Fundación Cardiovascular de Colombia

Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

salicylic acid/nekrose

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease

Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid

Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Den mest komplette database med medicinske urter understøttet af videnskab